JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46
JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and lowers the price target from $52 to $46.
Read original at benzingaStocks · News reference
Olema Pharmaceuticals Q2 EPS $(0.61) Misses $(0.55) Estimate
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.55) by 10.91 percent. This is a 19.61 percent decrease over losses of $(0.51) per
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 8:29 PM
- Checked
- Aug 10, 2026, 8:29 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Olema Pharmaceuticals, Inc. (OLMA)
Filed: 2026-08-13 AccNo: 0001193125-26-347853 Size: 593 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarOlema Oncology Announces Appointment Of Jason O'Byrne As CFO
Read original at benzingaCitigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.
Read original at benzinga